With a never-ending increase in red tape across the healthcare industry, you might be surprised to learn that ‘gender-affirming care’ for children appears to be escaping strict regulation.
In Senate Estimates, the Therapeutic Goods Administration (TGA) confirmed they are happy to vacate the field on the administration of puberty blockers and cross-sex hormones to children, admitting they see no need to micromanage the prescription of such drugs off-label.
As reported by The Australian, Therapeutic Goods Administration Chief Medical adviser Robyn Langham was asked about the regulation of puberty blockers being prescribed off-label to children as young as 10 years old.
Professor Langham said it...
Already a subscriber? Log in
Subscribe for just $2 a week
Try a month of The Spectator Australia absolutely free and without commitment. Not only that but – if you choose to continue – you’ll pay just $2 a week for your first year.
- Unlimited access to spectator.com.au and app
- The weekly edition on the Spectator Australia app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Or
Comments
Don't miss out
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
SUBSCRIBEAlready a subscriber? Log in